Display options
Cite
Hiramine S, Furusyo N, Ogawa E, et al. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol. 2015;7(26):2688-95doi: 10.4254/wjh.v7.i26.2688.
Hiramine, S., Furusyo, N., Ogawa, E., Nakamuta, M., Kajiwara, E., Nomura, H., Dohmen, K., Takahashi, K., Satoh, T., Azuma, K., Kawano, A., Koyanagi, T., Kotoh, K., Shimoda, S., & Hayashi, J. (2015). Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World journal of hepatology, 7(26), 2688-95. https://doi.org/10.4254/wjh.v7.i26.2688
Hiramine, Satoshi, et al. "Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C." World journal of hepatology vol. 7,26 (2015): 2688-95. doi: https://doi.org/10.4254/wjh.v7.i26.2688
Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol. 2015 Nov 18;7(26):2688-95. doi: 10.4254/wjh.v7.i26.2688. PMID: 26609346; PMCID: PMC4651913.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2015 Nov 18;7(26):2688-95. doi: 10.4254/wjh.v7.i26.2688.

Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.

World journal of hepatology

Satoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi

Affiliations

  1. Satoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.

PMID: 26609346 PMCID: PMC4651913 DOI: 10.4254/wjh.v7.i26.2688

Abstract

AIM: To investigate the efficacy of virological response (VR) to telaprevir (TVR)-based triple therapy in predicting treatment outcome of hepatitis C.

METHODS: This prospective, multicenter study consisted of 253 Japanese patients infected with hepatitis C virus (HCV) genotype 1b. All received 12 wk of TVR in combination with 24 wk of pegylated-interferon-α (IFN-α) and ribavirin. Serum HCV RNA was tested at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. VR was defined as undetectable serum HCV RNA. Sustained virological response (SVR) was VR at 24 wk after the end of treatment and was regarded as a successful outcome.

RESULTS: Of 253 patients, 207 (81.8%) achieved SVR. The positive predictive value of VR for SVR was 100% at week 2, after which it gradually decreased, and was over 85% to week 12. The negative predictive value (NPV) gradually increased, reaching 100% at week 12. The upslope of the NPV showed a large increase from week 4 (40.6%) to week 6 (82.4%). There was a moderate concordance between the SVR and VR at week 6 (kappa coefficient = 0.44), although other VRs had poor concordance to SVR. Multiple logistic regression analysis extracted VR at week 6 (P < 0.0001, OR = 63.8) as an independent factor contributing to SVR. In addition, the interleukin-28B single nucleotide polymorphism and response to previous pegylated-IFN-α and ribavirin therapy were identified as independent factors for SVR.

CONCLUSION: VR at week 6, but not at week 4, is an efficient predictor of both SVR and non-SVR to TVR-based triple therapy.

Keywords: Chronic hepatitis C; Direct-acting antiviral agent; Early virological response; Rapid virological response; Response-guided treatment

References

  1. Clin Infect Dis. 2008 Jan 1;46(1):78-84 - PubMed
  2. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  3. Hepatol Res. 2014 Jan;44 Suppl S1:59-70 - PubMed
  4. World J Gastroenterol. 2013 Dec 21;19(47):8963-73 - PubMed
  5. J Hepatol. 2013 Oct;59(4):667-74 - PubMed
  6. J Hepatol. 2005 Sep;43(3):425-33 - PubMed
  7. N Engl J Med. 2011 Sep 15;365(11):1014-24 - PubMed
  8. J Gastroenterol Hepatol. 2008 Jul;23 (7 Pt 1):1094-104 - PubMed
  9. J Hepatol. 2014 Feb;60(2):392-420 - PubMed
  10. Hepatology. 1994 May;19(5):1321-4 - PubMed
  11. Hepatology. 2012 Aug;56(2):567-75 - PubMed
  12. J Infect Dis. 2008 Sep 15;198(6):800-7 - PubMed
  13. J Hepatol. 2013 Aug;59(2):205-12 - PubMed
  14. N Engl J Med. 2011 Jun 23;364(25):2405-16 - PubMed
  15. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  16. Hepatology. 1994 Jul;20(1 Pt 1):15-20 - PubMed
  17. Nature. 2009 Sep 17;461(7262):399-401 - PubMed
  18. PLoS One. 2011;6(9):e24907 - PubMed
  19. J Clin Microbiol. 2011 May;49(5):1853-60 - PubMed
  20. Hepatology. 2006 May;43(5):954-60 - PubMed
  21. Hepatology. 2008 Jun;47(6):1884-93 - PubMed

Publication Types